- $420.96m
- $132.77m
- $9.68m
Prothena dips after pricing equity offering
Brief: Prothena Announces Pricing Of Public Offering Of 3,250,000 Ordinary Shares
U.S. STOCKS ON THE MOVE-Pfizer, Harrow Health, Vallon Pharma
U.S. STOCKS ON THE MOVE-Processa Pharma, Solaredge, Immix Biopharma
Prothena slips on share offering launch
Brief: Prothena Announces Proposed Public Offering Of Ordinary Shares
Brief: Prothena Announces Achievement Of $40 Mln Clinical Milestone Payment From Novo Nordisk For Prx004/Nnc6019
Biogen, Eli Lilly rise after Roche Alzheimer's drug failure
Biogen, Eli Lilly rise after Roche Alzheimer's drug failure
Roche says Alzheimer's drug fails to meet goal in trial (updated)
Prothena Corporation PLC reports results for the quarter ended in September - Earnings Summary
Brief: Prothena To Present Data On Survival Benefit Observed In Completed Phase 3 Study Of Drug Candidate Birtamimab In Patients With Mayo Stage Iv Al Amyloidosis At The Ash 2022 Meeting
Prothena Corporation PLC expected to post a loss of 53 cents a share - Earnings Preview
Prothena Corporation PLC expected to post a loss of 53 cents a share - Earnings Preview
Alzheimer's drug developers soar after Biogen's "unequivocal win"
Biogen, Eisai stocks soar on Alzheimer's success, lifting rival shares (updated)
Prothena Corporation PLC reports results for the quarter ended in June - Earnings Summary
Brief: Prothena Reports Q2 Revenue $1.3 Mln
Brief: Prothena Reports Qtrly Loss Per Share $0.88